HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting of cytosolic phospholipase A2α impedes cell cycle re-entry of quiescent prostate cancer cells.

Abstract
Cell cycle re-entry of quiescent cancer cells has been proposed to be involved in cancer progression and recurrence. Cytosolic phospholipase A2α (cPLA2α) is an enzyme that hydrolyzes membrane glycerophospholipids to release arachidonic acid and lysophospholipids that are implicated in cancer cell proliferation. The aim of this study was to determine the role of cPLA2α in cell cycle re-entry of quiescent prostate cancer cells. When PC-3 and LNCaP cells were rendered to a quiescent state, the active form of cPLA2α with a phosphorylation at Ser505 was lower compared to their proliferating state. Conversely, the phospho-cPLA2α levels were resurgent during the induction of cell cycle re-entry. Pharmacological inhibition of cPLA2α with Efipladib upon induction of cell cycle re-entry inhibited the re-entry process, as manifested by refrained DNA synthesis, persistent high proportion of cells in G0/G1 and low percentage of cells in S and G2/M phases, together with a stagnant recovery of Ki-67 expression. Simultaneously, Efipladib prohibited the emergence of Skp2 while maintained p27 at a high level in the nuclear compartment during cell cycle re-entry. Inhibition of cPLA2α also prevented an accumulation of cyclin D1/CDK4, cyclin E/CDK2, phospho-pRb, pre-replicative complex proteins CDC6, MCM7, ORC6 and DNA synthesis-related protein PCNA during induction of cell cycle re-entry. Moreover, a pre-treatment of the prostate cancer cells with Efipladib during induction of cell cycle re-entry subsequently compromised their tumorigenic capacity in vivo. Hence, cPLA2α plays an important role in cell cycle re-entry by quiescent prostate cancer cells.
AuthorsMu Yao, Chanlu Xie, Mei-Yee Kiang, Ying Teng, David Harman, Jessamy Tiffen, Qian Wang, Paul Sved, Shisan Bao, Paul Witting, Jeff Holst, Qihan Dong
JournalOncotarget (Oncotarget) Vol. 6 Issue 33 Pg. 34458-74 (Oct 27 2015) ISSN: 1949-2553 [Electronic] United States
PMID26416244 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzoates
  • Sulfonamides
  • Group IV Phospholipases A2
  • PLA2G4A protein, human
  • efipladib
Topics
  • Animals
  • Benzoates (pharmacology)
  • Cell Cycle (drug effects, physiology)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects, physiology)
  • Flow Cytometry
  • Fluorescent Antibody Technique
  • Group IV Phospholipases A2 (metabolism)
  • Heterografts
  • Humans
  • Immunoblotting
  • Immunohistochemistry
  • Male
  • Mice
  • Mice, Nude
  • Prostatic Neoplasms (enzymology, pathology)
  • Sulfonamides (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: